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Human herpesvirus 8-associated
primary effusion lymphoma in human
immunodeficiency virus-negative
patients: a clinico-epidemiologic variant
resembling classic Kaposi's sarcoma
The term primary effusion lymphoma (PEL)
defines an extranodal non-Hodgkin’s lymphoma,
usually classified as a B-cell lymphoma, that grows
in liquid-phase within body cavities. A mandatory
requisite for the diagnosis is the demonstration of
human herpesvirus 8 (HHV-8) genome within
tumor cells. HHV8 was first identified in late 1994
within acquired immunodeficiency syndrome
(AIDS)-Kaposi’s sarcoma (KS) lesions,1 subsequent-
ly in classic, iatrogenic, and endemic (African) KS
variants2,3 and finally, in 1995, within large-cell
type, AIDS-related intracavitary lymphomas.4 HHV-
8 infection is also associated with multicentric
Castleman’s disease5 and a range of post-trans-
plantation hematologic conditions, such as bone
marrow failure6 and lymphoproliferative disor-
ders.7,8 In 1996, body cavity based lymphomas har-
boring HHV-8 were proposed as a new entity with
the name of PEL, to be distinguished from other
primary and secondary lymphomatous effusions.9
PEL typically presents with recurrent effusions
but without a solid component. The most common
sites of involvement are the pleural, peritoneal and
pericardial cavities delimited by mesothelium.
Tumor cells may be co-infected by Epstein-Barr
virus (EBV) and show large-cell morphology, with
plasmablastic or immunoblastic features. Immu-
nophenotypic features include positive staining for
CD45, CD45R0, CD138, and activation-associated
antigens, and negative staining for B-/T-cell-asso-
ciated antigens. PEL cases exhibiting aberrant
expression of B-, T- and NK-markers have also been
reported. The B-cell lineage derivation of PEL cells
is established on the basis of clonal rearrangements
of the heavy immunoglobulin (Ig) genes and recent
polymerase chain reaction (PCR)-based findings of
a preferential expression of certain lambda light
chain genes, suggesting clonal proliferation by an
antigen selection process.10 In contrast to other
non-Hodgkin’s B-cell lymphoma types, neither c-
MYC nor other proto-oncogene rearrangements are
detected in PEL. Likewise, a wild type of the tumor
suppressor gene p53 is expressed, while mutations
of the BCL6 5’ non-coding regions have been
recently documented in most of the analyzed cas-
es.11 PEL cells show complex karyotypes, the most
frequent chromosomal abnormalities being trisomy
7, 12 and aberrations of chromosomal bands 1q21-
q25.11 The postulated normal cell(s) counterpart is
unknown, but the expression of CD138/syndecan-
1 and CD45R0 antigens, together with frequent
BCL6 mutations reflect a late stage of B-cell dif-
ferentiation.12 Recently, the expression status of
MUM1/IRF4 (multiple myeloma 1/interferon regu-
latory factor 4) protein, which is involved in phys-
iologic B-cell maturation, has been shown to clus-
ter selectively with PEL among lymphomatous effu-
sions, corroborating the notion that PEL originates
from post-germinal center, preterminally differen-
tiated B-cells.13
As to disease pathogenesis, the role of HHV-8 in
PEL development is widely accepted, whereas more
controversy exists on possible co-factors that may
trigger the transformation of HHV-8-infected lym-
phoid cells and their tropism for body cavities.
Over the last few years, PEL has been mainly
described in human immunodeficiency virus (HIV)-
positive patients.4,9,14 In the non-HIV setting, this
entity remains almost unreported but it may be
hypothesized that its epidemiology correlates with
the distribution of HHV-8 infection, which is
known to have a peculiar ethnic/geographic pat-
tern, being higher in the ethnic groups at risk for
classic KS, namely those of Jewish descent or those
living in the Mediterranean basin (i.e. Israel, Greece,
Spain and Italy)15-17 and sub-Saharan Africa.18 So
far, two examples of PEL have been reported in
HIV-negative transplant recipients, one from Haiti19
and one from Italy,20 but none from sub-Saharan
Africa where KS accounts for a high proportion of
all malignancies. However, one case of a black man
from South Africa with KS and unexplained pleur-
al effusions containing bizarre cells was reported
prior to the discovery of HHV-8.21 To date, there
are 20 well-documented cases developing in elder-
ly subjects9, 22,23,34 or even in centenarians35 of East-
ern European/Mediterranean or Jewish ancestry,
supporting the existence of a distinct clinico-epi-
demiologic variant of PEL paralleling classic KS, i.e.
classic PEL, as recently suggested also by Klepfish
et al.34
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Table 1 summarizes the available data concern-
ing classic PEL. The major distinguishing features of
this variant in comparison to the more common
AIDS-related PEL are an older age at presentation,
apparent host immunocompetence except for
functional immune senescence, a less aggressive
clinical course in a subset of patients, and infre-
quent EBV co-infection of the tumor clone. The
almost exclusive EBV negativity (26% of the cases
in contrast to 70-80% of AIDS-PEL) points out an
EBV-independent role for HHV-8 in the pathogen-
esis of PEL. Overall, these studies show several epi-
demiologic and clinical features that this form of
PEL shares with classic KS.36 Nevertheless, it is
notable that synchronous or metachronous KS is
rare in PEL.
The origin/descent of patients is from countries
where high rates of the incidence of both classic KS
and HHV8 seropositivity are observed. One third of
classic PEL are of Italian origin. The first case of non-
AIDS PEL was reported in 1996.23 The other five cas-
es were collected in two institutions during a 6-year
period (1995-2001; University of Rome La Sapien-
za28, and University of Modena) and consist of HIV–,
HBsAg–, and HCV-negative males who were born
in Italy and have lived in this country all their life.
Other reports include a number of cases among Jews
in Israel or immigrants in North African countries.
Clinical features similar to those of classic KS are
the overwhelming male predominance, seventh
decade of life at diagnosis (mean, 79.9; range 58-
101 years), minor immunosuppression (low leuko-
cyte and CD4 lymphocytes counts) and/or immu-
noactivation (elevated β2-microglobulin values),37
moderate anemia (hematocrit <30%, hypogly-
cemia and, less commonly, pruritus or erythema-
tous skin rash). Also, the 2-fold increase in risk of
KS for birthplace in area endemic for malaria in
the past38 and history of malaria found in classic KS
seems to be reproducible in classic PEL. PEL occur-
ring as a second primary neoplasm in 2 patients
with colon cancer is an intriguing – but difficult to
explain – finding. Cancer-related immune dys-
function might be a relevant risk factor.
Two special forms of edema causing body cavity
effusions appear to be frequently associated with
classic PEL: congestive heart failure (with pleural
PEL, often bilateral) that is also found in patients
with classic KS more often than expected, and cir-
rhosis (for peritoneal PEL). Although there are no
clinical data confirming the presence of pleural or
peritoneal effusion prior to the diagnosis of PEL in
a given patient, water retention in the form of
hydrothorax and ascites is a common finding in
chronic heart failure and cirrhosis, respectively.
These edematous states could facilitate the process
of lymphomagenesis by continuous accumulation
of excess fluid (ultrafiltrate of plasma with low pro-
tein content) and cells (mesothelial cells, macro-
phages, polymorphonuclear cells and lymphocytes,
and lymphomatous precursors) within body cavi-
ties. Herein, there might be favorable conditions for
the growth of HHV-8-infected cells via release of
various cytokines and inflammatory mediators39
similarly to the situation in KS, in which inflamma-
tory cytokines co-operate to induce angiogenesis,
edema, and lesion formation.40 Human interleukin-
6 secreted by mesothelium induces vascular
endothelial growth factor, which in turn can
increase vascular permeability, critical to the patho-
genesis of PEL.41 This hypothesis is supported by the
occurrence of lymphomatous effusions other than
PEL complicating ascites due to cirrhosis.42-44
The pathogenesis of PEL shares some aspects
with that of KS, including the model according to
which both diseases are cytokine-mediated dis-
eases originating as polyclonal expansions with
subsequent evolution to clonal proliferations.45 It
can be speculated that PEL-progenitors (circulat-
ing in the peripheral blood mononuclear cell frac-
tion, like KS-progenitors) may undergo viral repli-
cation when exposed to inflammatory sites or
cytokine-rich environments. Independent HHV-8-
infected clones may outgrow following a prema-
lignant/hyperplastic stage. Patients infected with
HHV-8 may develop non-lymphomatous body cav-
ity effusions containing HHV-8 DNA and mononu-
clear cells that are reminiscent of a reactive process
(early inflammatory stage? pre-lymphomatous
effusion?) similar to early, inflammatory KS.46 In
the tumoral stage of PEL, fluids show a peculiar
appearance of scattered lymphomatous cells in a
heavy inflammatory background. Consistent with
this hypothesis, a few cases of full-blown PEL of
polyclonal nature have been reported both in HIV-
infected and HIV-uninfected patients.
PEL is usually highly aggressive.4,17 However, the
natural history of the classic variant is more het-
erogeneous. In the surveyed articles, only a minor-
ity of patients had a very aggressive course with
death within 6 months. Others experienced pro-
longed survival, partial or complete regression and
even remission after simple thoracentesis or tho-
racentesis plus local anti-viral therapy or
chemotherapy. As occurs with classic KS, in which
patients often die of other causes, the actual cause
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of death is not well defined.
Given the steady increase of the elderly popula-
tion and the decline in immune status associated
with physiologic aging, classic PEL may represent
an emerging disease in those areas that are
endemic for HHV-8 infection. However, establish-
ing a diagnosis of PEL is a challenge. PEL is not as
easy to discover as KS, which is visually identified,
since it is an out-of-sight disease. Patients are first
seen by general physicians or internists more fre-
quently than by hematologists, in view of the fact
that the key complaints are shortness of breath,
pleuritic chest pain, and fever because of the
underlying pleural effusion or ascites. The diagno-
sis is first made from routine cytology plus
immunophenotyping studies but requires, as an
essential step, the molecular demonstration of
HHV-8. In fact, failure to detect HHV-8 DNA
sequences precludes a diagnosis of PEL. Immuno-
histochemistry, using commercially available mon-
oclonal antibodies directed against the latent
nuclear antigen (LNA-1) ORF-73, is also useful for
detecting HHV-8. Knowledge of HHV-8 epidemiol-
ogy and of the variety of risk indicators is needed
to identify classic PEL. The therapeutic approach,
which is far from being settled, should be aimed at
both reducing viral activity and eradicating pre-
disposing host-factors favoring edematous states.
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